CVSC Cardiovascular Sciences Inc (CE)

The board of directors of Cardiovascular Sciences, Inc. (Pink Sheets:CVSC) (the "Company") is eager to announce that it is entering into the next phase of development with its partnership with MedTech Enterprises. Cardiovascular Sciences, Inc. is a client company of the award-winning University of Central Florida's Technology Incubator program. MedTech Enterprises is the company�s division readying to spring forth with a retail internet program to market a premium antioxidant, anti-aging nutritional supplement. Over the past six weeks, the company has arranged for the production of a premium antioxidant supplement containing nutrients scientifically proven to reduce cholesterol levels which may reduce the risk of heart disease when taken with a diet low in saturated fats and cholesterol. The production of the product is nearing completion and a label for the Company�s Cell Renewal Formula has cleared the regulatory compliance hurdle. The product is scheduled for release later this month. �We are very enthused and anxious to launch our supplement which has been formulated to include the latest developments in the area of antioxidant supplementation,� exclaims the company�s President/CEO, Dr. Larry Hooper. �In addition to our direct marketing, we have also met recently with a number of individuals interested in carrying our proprietary core antioxidant to a variety of markets.� In addition to the Company�s core product entry into this field, a number of vendor agreements have been reached to distribute a number of additional health-benefiting products. The company envisions growing a line of various select and complementary products, all with a focused goal of benefiting health, enabling prevention and insuring longevity. Jev Conover, a member of the board of directors and the CEO of a prominent hospital in the Midwest, added, �We see this endeavor to develop a line of products with prominent health benefits as a natural extension of the Company�s continuing efforts to develop its antiadhesion technology whose benefits are also to insure improved health and prevent illness and disability.� About Cardiovascular Sciences, Inc. Cardiovascular Sciences, Inc. is an advanced medical device company which is developing a novel technology platform to address the problem of post-surgical and post-traumatic adhesions. Adhesions and the complications of adhesions are a significant problem worldwide for a wide range of specialists, including general surgeons, cardiothoracic surgeons, orthopedic, plastic, and ophthalmologic and otolaryngology specialists to name just some of them. In addition, the veterinary field has a tremendous need for a product that can prevent similar problems in a wide variety of animals. The Company's unique materials and processes promise a more cost-effective and decidedly more efficient and capable means to deal with a problem that has been so devastating to so many. Current sponsored research at the University of Central Florida (UCF) and previously at other institutions indicate that The Company is on the right path and progressing well. In addition to the anti-adhesion technology, The Company owns technology in a variety of other areas, including thrombo-resistant coatings, enhanced intra-arterial balloon pumping catheters, cell-engineered vascular tissues, and a method for improved recovery of the heart following cardioplegia. This yields a diversified portfolio with projects in various stages of development. www.cvsciences.org Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks, and uncertainties and actual results could differ from those discussed. This material is information only and is not an offer or solicitation to buy or sell the securities.